Evidence map›Paper›PMID 24817974›Full record

ReviewInternational journal of clinical and experimental pathology2014

Occurrence of Epstein-Barr virus-associated plasmacytic lymphoproliferative disorder after antithymocyte globulin therapy for aplastic anemia: a case report with review of the literature.

Ryota Nakanishi, Mitsuaki Ishida, Keiko Hodohara, Hiroko Okuno, Miyuki Yoshii, Akiko Horinouchi, Ayaka Shirakawa, Ayumi Harada, Muneo Iwai, Keiko Yoshida and 3 more

Open access · greenAbstract readCase ReportsReview
PubMed Full text at PMC
In one paragraph

Review in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Ryota NakanishiDepartment of Clinical Laboratory Medicine, Shiga University of Medical Science Shiga, Japan.
Mitsuaki IshidaDepartment of Clinical Laboratory Medicine, Shiga University of Medical Science Shiga, Japan ; Division of Diagnostic Pathology, Shiga University of Medical Science Shiga, Japan.
Keiko HodoharaDepartment of Hematology, Shiga University of Medical Science Shiga, Japan.
Hiroko OkunoDepartment of Clinical Laboratory Medicine, Shiga University of Medical Science Shiga, Japan.
Miyuki YoshiiDepartment of Clinical Laboratory Medicine, Shiga University of Medical Science Shiga, Japan.
Akiko HorinouchiDepartment of Clinical Laboratory Medicine, Shiga University of Medical Science Shiga, Japan.
Ayaka ShirakawaDepartment of Clinical Laboratory Medicine, Shiga University of Medical Science Shiga, Japan.
Ayumi HaradaDepartment of Clinical Laboratory Medicine, Shiga University of Medical Science Shiga, Japan.
Muneo IwaiDivision of Diagnostic Pathology, Shiga University of Medical Science Shiga, Japan.
Keiko YoshidaDivision of Diagnostic Pathology, Shiga University of Medical Science Shiga, Japan.
Akiko KagotaniDivision of Diagnostic Pathology, Shiga University of Medical Science Shiga, Japan.
Takashi YoshidaDepartment of Clinical Laboratory Medicine, Shiga University of Medical Science Shiga, Japan.
Hidetoshi OkabeDepartment of Clinical Laboratory Medicine, Shiga University of Medical Science Shiga, Japan ; Division of Diagnostic Pathology, Shiga University of Medical Science Shiga, Japan.
Shiga University of Medical Science · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is well established that patients with immunosuppression have a higher risk of development of lymphoproliferative disorders (LPDs), and Epstein-Barr virus (EBV) is associated with development of LPDs. Aplastic anemia (AA) is an immune-mediated hematological disorder, and immunosuppression therapy (IST), such as antithymocyte globulin (ATG), is widely used for treatment of AA. However, occurrence of LPD without bone marrow transplantation has been extremely rarely documented in patients with IST for AA. Herein, we report the 6th documented case of EBV-associated LPD after IST for AA and review the clinicopathological features of this extremely rare complication. A 46-year-old Japanese female was admitted for evaluation of progressive pancytopenia. Bone marrow biopsy revealed fatty marrow with marked decrease of trilineage cells, and bone marrow aspiration demonstrated no dysplastic changes. IST with rabbit ATG was administered, after which, she developed high fever. Bone marrow aspiration showed increase of atypical plasma cells with mildly enlarged nuclei and irregular nuclear contour. These atypical plasma cells were EBER-positive. Accordingly, a diagnosis of EBV-positive plasmacytic LPD was made. Most cases of LPDs are B-cell origin, and plasmacytic LPD is a rare subtype. The current report is the second case of plasmacytic LPD in patients with IST for AA. Therefore, detailed histopathological and immunohistochemical analyses are needed for correct diagnosis and treatment, and additional studies are needed to clarify the clinicopathological features of EBV-LPD after IST for AA.

Indexed as

Anemia, AplasticAntilymphocyte SerumAntiviral AgentsBiopsyBone MarrowEpstein-Barr Virus InfectionsFemaleHumansImmunosuppression TherapyLymphoproliferative DisordersMiddle AgedTreatment OutcomeWithholding TreatmentAntilymphocyte SerumAntiviral Agentsantithymocyte globulin therapyaplastic anemiaEpstein-Barr virus-associated lymphoproliferative disorder

Identifiers

PMID24817974
PMCPMC4014258
OpenAlexW241845724

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.